Amplification of chromosome 11q13 has been reported in up to 15% of patients with breast cancer and is associated with endocrine therapy resistance and poor prognosis, particularly for ER-positive and invasive lobular carcinomas [44–46]. Here, ESR1 is linked to invasive lobular breast carcinoma.